168 related articles for article (PubMed ID: 6481426)
1. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.
Stewart DJ; Richard MT; Hugenholtz H; Dennery JM; Belanger R; Gerin-Lajoie J; Montpetit V; Nundy D; Prior J; Hopkins HS
J Neurooncol; 1984; 2(2):133-9. PubMed ID: 6481426
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of intracarotid etoposide.
Savaraj N; Feun LG; Lu K; Wallace S; Fields WS; Loo TL
Cancer Chemother Pharmacol; 1986; 16(3):292-4. PubMed ID: 3698170
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
5. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
Postmus PE; Holthuis JJ; Haaxma-Reiche H; Mulder NH; Vencken LM; van Oort WJ; Sleijfer DT; Sluiter HJ
J Clin Oncol; 1984 Mar; 2(3):215-20. PubMed ID: 6321690
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination chemotherapy.
Morikawa N; Mori T; Abe T; Kawashima H; Takeyama M; Hori S
Biol Pharm Bull; 1999 Apr; 22(4):428-31. PubMed ID: 10328568
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of etoposide in gestochoriocarcinoma.
D'Incalci M; Sessa C; Rossi C; Roviaro G; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):69-72. PubMed ID: 2981622
[TBL] [Abstract][Full Text] [Related]
8. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration.
Kiya K; Uozumi T; Ogasawara H; Sugiyama K; Hotta T; Mikami T; Kurisu K
Cancer Chemother Pharmacol; 1992; 29(5):339-42. PubMed ID: 1312906
[TBL] [Abstract][Full Text] [Related]
9. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
Colombo T; Broggini M; Vaghi M; Amato G; Erba E; D'Incalci M
Eur J Cancer Clin Oncol; 1986 Feb; 22(2):173-9. PubMed ID: 3699080
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability and pharmacokinetics of etoposide (VP-16).
Smyth RD; Pfeffer M; Scalzo A; Comis RL
Semin Oncol; 1985 Mar; 12(1 Suppl 2):48-51. PubMed ID: 3975657
[TBL] [Abstract][Full Text] [Related]
11. The effect of dose on the bioavailability of oral etoposide.
Harvey VJ; Slevin ML; Joel SP; Johnston A; Wrigley PF
Cancer Chemother Pharmacol; 1986; 16(2):178-81. PubMed ID: 3004772
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.
Allen LM; Creaven PJ
Eur J Cancer (1965); 1975 Oct; 11(10):697-707. PubMed ID: 1204664
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.
Brindley CJ; Antoniw P; Newlands ES; Bagshawe KD
Cancer Chemother Pharmacol; 1985; 15(1):66-71. PubMed ID: 4039984
[TBL] [Abstract][Full Text] [Related]
14. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
[TBL] [Abstract][Full Text] [Related]
15. Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.
Stewart DJ; Richard MT; Hugenholtz H; Dennery J; Nundy D; Prior J; Montpetit V; Hopkins HS
J Neurooncol; 1984; 2(4):315-24. PubMed ID: 6530619
[TBL] [Abstract][Full Text] [Related]
16. Human central nervous system pharmacology of pentamethylmelamine and its metabolites.
Stewart DJ; Benvenuto JA; Leavens M; Smith RG; Cabanillas F; Benjamin RS; Loo TL
J Neurooncol; 1983; 1(4):357-64. PubMed ID: 6432969
[TBL] [Abstract][Full Text] [Related]
17. Etoposide (VP-16-213) in malignant brain tumors: a phase II study.
Tirelli U; D'Incalci M; Canetta R; Tumolo S; Franchin G; Veronesi A; Galligioni E; Trovò MG; Rossi C; Grigoletto E
J Clin Oncol; 1984 May; 2(5):432-7. PubMed ID: 6726296
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.
Strife RJ; Jardine I; Colvin M
J Chromatogr; 1980 May; 182(2):211-20. PubMed ID: 7380913
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.
D'Incalci M; Erba E; Vaghi M; Morasca L
Eur J Cancer Clin Oncol; 1982 Apr; 18(4):377-80. PubMed ID: 6889515
[TBL] [Abstract][Full Text] [Related]
20. Human central nervous system and plasma pharmacology of mitoxantrone.
Green RM; Stewart DJ; Hugenholtz H; Richard MT; Thibault M; Montpetit V
J Neurooncol; 1988; 6(1):75-83. PubMed ID: 3397768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
